Tudor Investment Corp
CRSP icon

Tudor Investment Corp’s CRISPR Therapeutics CRSP Stock Holding History

Tudor Investment Corp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Sell
42,512
-899
-2% -$47.4K ﹤0.01% 1845
2026
Q1 		$2.07M Buy
43,411
+3,943
+10% +$208K ﹤0.01% 1829
2025
Q4 		$2.07M Buy
+39,468
New +$2.36M ﹤0.01% 1785
2025
Q2 		– Sell
-51,242
Closed -$1.98M – 3334
2025
Q1 		$1.74M Buy
51,242
+32,905
+179% +$1.39M 0.01% 1443
2024
Q4 		$722K Sell
18,337
-28,662
-61% -$1.35M ﹤0.01% 1970
2024
Q3 		$2.21M Buy
+46,999
New +$2.38M 0.01% 1140
2024
Q2 		– Sell
-21,790
Closed -$1.49M – 2388
2024
Q1 		$1.49M Buy
21,790
+5,741
+36% +$411K 0.01% 1164
2023
Q4 		$1M Buy
+16,049
New +$887K 0.01% 1437
2023
Q3 		– Sell
-25,562
Closed -$1.44M – 2371
2023
Q2 		$1.44M Buy
+25,562
New +$1.45M 0.02% 1085
2023
Q1 		– Sell
-24,949
Closed -$1.01M – 2499
2022
Q4 		$1.01M Buy
24,949
+1,056
+4% +$56K 0.02% 1094
2022
Q3 		$1.56M Buy
23,893
+4,211
+21% +$305K 0.03% 638
2022
Q2 		$1.2M Sell
19,682
-5,301
-21% -$312K 0.03% 781
2022
Q1 		$1.57M Sell
24,983
-4
-0% -$251 0.04% 671
2021
Q4 		$1.89M Buy
24,987
+3,701
+17% +$323K 0.03% 661
2021
Q3 		$2.38M Buy
+21,286
New +$2.67M 0.04% 601
2021
Q1 		– Sell
-15,841
Closed -$2.42M – 1604
2020
Q4 		$2.42M Buy
15,841
+8,858
+127% +$1.05M 0.07% 346
2020
Q3 		$584K Buy
6,983
+1,916
+38% +$170K 0.03% 755
2020
Q2 		$372K Sell
5,067
-6,182
-55% -$361K 0.02% 813
2020
Q1 		$477K Sell
11,249
-5,484
-33% -$283K 0.04% 511
2019
Q4 		$1.02M Buy
+16,733
New +$914K 0.05% 489
2018
Q2 		– Sell
-8,608
Closed -$393K – 1070
2018
Q1 		$393K Buy
+8,608
New +$355K 0.01% 649

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tudor Investment Corp's CRSP Position: Q2 2026 in Review

Tudor Investment Corp reduced its CRISPR Therapeutics (CRSP) stake by 2.1% in Q2 2026, selling an estimated $47.4K and leaving 42,512 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Tudor Investment Corp first reported a position in CRSP in Q1 2018 and has held it in 21 quarters since. The position peaked at $2.42M in Q4 2020. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Tudor Investment Corp held 42,512 shares of CRISPR Therapeutics worth $2.32M as of Q2 2026.
  • Tudor Investment Corp sold 899 CRISPR Therapeutics shares in Q2 2026, an estimated $47.4K.
  • CRISPR Therapeutics made up ﹤0.01% of Tudor Investment Corp's portfolio in Q2 2026, its #1845 holding.
  • Tudor Investment Corp first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 21 quarters since.
  • Tudor Investment Corp's CRISPR Therapeutics position peaked at $2.42M in Q4 2020.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.